Key Highlights: Implications: If completed, the transaction would likely be a strong validation event for mid-sized Indian pharmaceutical businesses that combine branded generics, nu...
Key Highlights: Implications: The launch positions Eisai to capture first-mover advantage in India’s underpenetrated dementia market, where prevalence is already large and expected t...
Key Highlights: Implications: Wegovy’s new MASH indication turns semaglutide into a dual liver–weight disease asset in India, opening a large, under-treated fatty liver market (about two i...
Key Highlights: Implications: Poviztra’s new MASH label lets Emcure plug innovator semaglutide directly into India’s emerging fatty liver treatment market, riding on ESSENCE data (63% stea...
